ATE218864T1 - Verwendung von piperidin-derivaten in der behandlung von schizophrenie - Google Patents

Verwendung von piperidin-derivaten in der behandlung von schizophrenie

Info

Publication number
ATE218864T1
ATE218864T1 AT94924708T AT94924708T ATE218864T1 AT E218864 T1 ATE218864 T1 AT E218864T1 AT 94924708 T AT94924708 T AT 94924708T AT 94924708 T AT94924708 T AT 94924708T AT E218864 T1 ATE218864 T1 AT E218864T1
Authority
AT
Austria
Prior art keywords
schizophrenia
treatment
piperidine derivatives
mammal
sulphur
Prior art date
Application number
AT94924708T
Other languages
English (en)
Inventor
Franklin Porter Bymaster
Harlan E Shannon
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Application granted granted Critical
Publication of ATE218864T1 publication Critical patent/ATE218864T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT94924708T 1993-08-19 1994-08-15 Verwendung von piperidin-derivaten in der behandlung von schizophrenie ATE218864T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10930093A 1993-08-19 1993-08-19
PCT/DK1994/000305 WO1995005174A1 (en) 1993-08-19 1994-08-15 Antipsychotic method

Publications (1)

Publication Number Publication Date
ATE218864T1 true ATE218864T1 (de) 2002-06-15

Family

ID=22326932

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94924708T ATE218864T1 (de) 1993-08-19 1994-08-15 Verwendung von piperidin-derivaten in der behandlung von schizophrenie

Country Status (23)

Country Link
EP (1) EP0734259B1 (de)
JP (1) JP3126736B2 (de)
KR (1) KR100360575B1 (de)
CN (1) CN1087936C (de)
AT (1) ATE218864T1 (de)
AU (1) AU701292B2 (de)
CA (1) CA2169839C (de)
CZ (1) CZ285030B6 (de)
DE (1) DE69430816T2 (de)
DK (1) DK0734259T3 (de)
ES (1) ES2177581T3 (de)
FI (2) FI960747A7 (de)
HU (1) HU221729B1 (de)
IL (1) IL110708A (de)
NO (1) NO312706B1 (de)
NZ (2) NZ271311A (de)
PT (1) PT734259E (de)
RU (1) RU2191580C2 (de)
SG (1) SG55071A1 (de)
TW (1) TW442284B (de)
UA (1) UA63876C2 (de)
WO (1) WO1995005174A1 (de)
ZA (1) ZA946324B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821371A (en) * 1994-10-24 1998-10-13 Eli Lilly And Comany Heterocyclic compounds and their preparation and use
US5998404A (en) * 1994-10-24 1999-12-07 Eli Lilly And Company Heterocyclic compounds and their use
US5605908A (en) * 1994-10-24 1997-02-25 Eli Lilly And Company Heterocyclic compounds and their use
US5726193A (en) * 1994-10-31 1998-03-10 Eli Lilly And Company Method for treating anxiety
US5488056A (en) * 1994-10-31 1996-01-30 Eli Lilly And Company Method for treating anxiety
US5574028A (en) * 1994-10-31 1996-11-12 Eli Lilly And Company Method for treating anxiety
ES2144581T3 (es) * 1994-10-31 2000-06-16 Lilly Co Eli Tetrahidropiridina oxadiazol o tiadiazol para tratar la ansiedad.
US5565475A (en) * 1994-11-08 1996-10-15 Muhlhauser; Mark A. Method of treating urinary bladder dysfunctions with 3-tetrahydropyridine derivatives
US5852037A (en) * 1995-11-13 1998-12-22 Eli Lilly And Company Method for treating anxiety
US5763457A (en) * 1995-11-13 1998-06-09 Eli Lilly And Company Method for treating anxiety
EP0821959A3 (de) * 1996-08-01 1998-09-16 Eli Lilly And Company Verwendung von 3-(4-Hexyloxy-1,2,5-Thiadiazol-3-yl)-1,2,5,6-Tetrahydro-1-Methylpyridin zur Behandlung von Nikotin-Entzug
EP0821954A1 (de) * 1996-08-01 1998-02-04 Eli Lilly And Company Verfahren zur Behandlung von geistiger Zurückgebliebenheit
EP0821957A3 (de) * 1996-08-01 1998-04-22 Eli Lilly And Company Verwendung von 3-(4-Hexyloxy-1,2,5-Thiadiazol-3-yl)-1,2,5,6-Tetrahydro-1-Methylpyridin (Xanomelin) zur Behandlung von Drogenmissbrauch
EP0821958A3 (de) * 1996-08-01 1998-07-08 Eli Lilly And Company Verwendung von 3-(4-Hexyloxy-1,2,5-Thiadiazol-3-yl)-1,2,5,6-Tetrahydro-1-Methylpyridin (Xanomelin) zur Behandlung von übermässiger Streitsucht
EP0821956A1 (de) * 1996-08-01 1998-02-04 Eli Lilly And Company Verfahren zur Behandlung disruptiver Verhaltensstörungen
US6043258A (en) * 1996-08-01 2000-03-28 Eli Lilly And Company Method for treating disruptive behavior disorders with xanomeline
ATE213413T1 (de) * 1996-08-01 2002-03-15 Lilly Co Eli Verwendung von 3-(4-hexyloxy-1,2,5-thiadiazol-3- yl)-1,2,5,6-tetrahydro-1-methylpyridin (xanomelin) zur behandlung von bipolaren störungen
US6090829A (en) * 1996-08-01 2000-07-18 Eli Lilly And Company Method for treating excessive aggression
US6117890A (en) * 1996-08-01 2000-09-12 Eli Lilly And Company Method for treating bipolar disorder
EP1014974B1 (de) * 1997-05-29 2004-08-11 H. Lundbeck A/S Behandlung der schizophrenie und der psychose
US6034108A (en) * 1997-07-28 2000-03-07 Eli Lilly And Company Method for treating mental retardation
HUE044653T2 (hu) 2009-07-22 2019-11-28 PureTech Health LLC Készítmények olyan rendellenességek kezelésére, amelyek muszkarin-receptor aktiválással enyhíthetõk
BR112021005802B1 (pt) * 2018-09-28 2022-02-15 Karuna Therapeutics, Inc Composição farmacêutica oral
US11534434B2 (en) 2019-11-15 2022-12-27 Karuna Therapeutics, Inc. Xanomeline derivatives and methods for treating neurological disorders
CN115974863B (zh) * 2021-10-14 2024-12-31 南京迈诺威医药科技有限公司 占诺美林衍生物的苹果酸盐、a晶型及其制备方法和用途
CN119161338B (zh) * 2024-11-25 2025-06-17 嘉兴安帝康生物科技有限公司 用作毒蕈碱受体激动剂的四氢吡啶衍生物及其在医药上的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ225999A (en) * 1987-09-10 1992-04-28 Merck Sharp & Dohme Azacyclic- or azabicyclic-substituted thiadiazole derivatives and pharmaceutical compositions
US5043345A (en) * 1989-02-22 1991-08-27 Novo Nordisk A/S Piperidine compounds and their preparation and use
DK198390D0 (da) * 1990-08-21 1990-08-21 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse
DK198490D0 (da) * 1990-08-21 1990-08-21 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse

Also Published As

Publication number Publication date
NZ336597A (en) 2001-02-23
DK0734259T3 (da) 2002-09-30
NO960619D0 (no) 1996-02-16
KR960703592A (ko) 1996-08-31
TW442284B (en) 2001-06-23
HU221729B1 (hu) 2002-12-28
UA63876C2 (en) 2004-02-16
CN1133008A (zh) 1996-10-09
CN1087936C (zh) 2002-07-24
DE69430816D1 (de) 2002-07-18
IL110708A (en) 1998-12-06
SG55071A1 (en) 1998-12-21
JP3126736B2 (ja) 2001-01-22
PT734259E (pt) 2002-11-29
ES2177581T3 (es) 2002-12-16
WO1995005174A1 (en) 1995-02-23
CZ285030B6 (cs) 1999-05-12
CA2169839A1 (en) 1995-02-23
FI960747L (fi) 1996-04-17
FI960747A7 (fi) 1996-04-17
HU9600364D0 (en) 1996-04-29
RU2191580C2 (ru) 2002-10-27
NO312706B1 (no) 2002-06-24
CZ42696A3 (en) 1996-11-13
JPH09501658A (ja) 1997-02-18
AU7490294A (en) 1995-03-14
AU701292B2 (en) 1999-01-21
NZ271311A (en) 1999-09-29
NO960619L (no) 1996-04-18
ZA946324B (en) 1996-02-19
IL110708A0 (en) 1994-11-11
DE69430816T2 (de) 2002-12-19
FI20050461L (fi) 2005-04-29
EP0734259A1 (de) 1996-10-02
FI960747A0 (fi) 1996-02-19
CA2169839C (en) 2002-06-11
FI20050461A7 (fi) 2005-04-29
EP0734259B1 (de) 2002-06-12
HUT75111A (en) 1997-04-28
KR100360575B1 (ko) 2003-03-10

Similar Documents

Publication Publication Date Title
DE69430816D1 (de) Verwendung von Piperidin-Derivaten in der Behandlung von Schizophrenie
DE69523350D1 (de) Behandlung von hyperproliferativen Gefässerkrankungen
DE69729946D1 (de) Verwendung von cyclooxygenase-2 inhibitoren zur behandlung und verbeugung von neoplasia
DE69402173D1 (de) Hemmung von Thrombin
ATE131166T1 (de) Pyranderivate zur verwendung als 5- lipoxygenasehemmer.
EP0613883A4 (de) Hydroxamsäure derivate.
EP0604641A4 (de) Zusammensetzung, die aminderivate oder aminverwandte derivate der benzoesäure enthält, und ihre verwendung einschliesslich der behandlung von entzündlichen erkrankungen.
DE68918809D1 (de) Verwendung von Benzimidazol-Derivaten bei der Behandlung von epithelialen Erkrankungen.
ATA16597A (de) Neue substituierte p-sulfonylaminobenzol- sulfonsäureamide
DE68929059D1 (de) N-Acylpyrrolidine, Verfahren zur Herstellung und ihre Verwendung zur Prevention und/oder Behandlung von Amnesie
DE69125216D1 (de) Aminoalkanesulfonsäurederivate und pharmazeutische Zusammensetzungen davon zur Prävention oder Behandlung von Herzerkrankungen
DE69808099D1 (de) Substituierte 6-alkylphenanthridine
ATE169217T1 (de) Verwendung von furanonderivaten zur vorbeugung oder behandlung von autoimmunkrankheiten
ATE180669T1 (de) Verwendung von pregnanderivaten zur behandlung von tumoren
ATE212845T1 (de) Verwendung von cytochrome - p 450 - inhibitoren zur hemmung des stoffwechsels von stickstoffsubstituierten acridinen
NO970340L (no) Organiske forbindelser
ATE239718T1 (de) 3-(1-methylethoxy)benzo(b)thiophen-2-carboxamid als inhibitoren der zelladhäsion
DE59403966D1 (de) Hydroxymethylfurazancarbonsäurederivate und ihre verwendung in der behandlung von kardiovaskulären erkrankungen
DE68903907D1 (de) Cyclisches peptid, seine herstellung und seine verwendung zur behandlung von cardiovasculaeren stoerungen.
NO20003481L (no) FremgangsmÕte for behandling av COPD
DE68921051D1 (de) Pyridin-3-percarboxylsäure monopersulfat.
ATE250027T1 (de) Azetidincarboxamidderivate zur behandlung von zns-erkrankungen
DE69619088D1 (de) Quinoxalin-Derivate zur Behandlung von Tinnitus
DE59504374D1 (de) Verwendung von Deoxyspergualin zur Herstellung eines Arzneimittels zur Behandlung von entzündlich-hyperreaktiven Erkrankungen
ATE178336T1 (de) Verwendung einer therapeutischen zusammensetzung zur behandlung von bronchitis

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee